The use of immune checkpoint inhibitors (ICIs) in combination therapy is an emerging trend in tumor immunology. However, the value of combination immunotherapy remains controversial, because of the toxic effects induced by combination. The added benefit of each additional drug has not been assessed against the added toxicity. We searched for clinical trials that evaluated ICI monotherapies and combination therapies in lung cancer and melanoma patients. The overall response rate (ORR), grade 3/4 treatment-related adverse event rate, overall survival (OS), and progression-free survival (PFS) were extracted from the most recently published studies to determine the relative risk (RR), hazard ratios (HRs), and 95% confidence intervals (CIs). Seven randomized controlled trials and one open-label study were identified (n 5 3,097). Treatments included combinations of several ICIs, a combination of an ICI and dacarbazine, two combinations of an ICI, paclitaxel and carboplatin, and a combination of an ICI and gp100 vaccine. Higher ORR (RR: 1.51, 95% CI: 1.03-2.20, p 5 0.034), OS (HR: 0.86, 95% CI: 0.78-0.95, p 5 0.000), and PFS (HR: 0.93, 95% CI: 0.72-1.14, p 5 0.000) values were observed in combination therapy than in monotherapy. In addition, the toxicity of combination ICI immunotherapy was higher (RR: 1.50, 95% CI: 1.03-2.19, p 5 0.036) than that of monotherapy. This meta-analysis showed that the addition of nivolumab to ipilimumab better benefits PFS and ORR. Adding sargramostim was associated with better OS and safety. The efficacy and safety of a nivolumab-ipilimumabsargramostim combination should be investigated further.
1
Although cancer therapies include surgery, radiation and chemotherapy, the overall survival (OS) rates of patients are still far from ideal. Cancer immunotherapy has become a focus of investigation, including research into immune checkpoint inhibitors (ICIs). Programmed death (PD) 1 inhibitors such as nivolumab or the cytotoxic T-lymphocyte-associated antigen (CTLA) 4 inhibitors such as ipilimumab have been approved by the US Food and Drug Administration (FDA). 2, 3 Several phase III randomized controlled trials (RCTs) have concluded that monotherapy with these agents can exert robust antitumor effects. CTLA-4, also termed CD152, is a protein receptor that functions as an immune checkpoint to regulate immune responses. Ipilimumab inhibits CTLA-4, and has been shown to improve OS in solid cancer patients. 4 PD-1, also termed CD279, is another immune-checkpoint receptor and is expressed on T cells. PD-1 can prevent T cell activity in parenchyma. Nivolumab is a monoclonal IgG4-blocking PD-1 antibody; it can activate the host immune system and act against tumor cells, displaying approximately a 20% objective response rate. Anti-PD-1 drugs can significantly improve the OS of patients. 5 ICI combination immunotherapy has recently gained popularity, 6 and there are several preclinical trials on ICI combination immunotherapy, [7] [8] [9] as well as phase I and phase II studies 10, 11 . Published reviews have touted the merits of combination immunotherapy. 12, 13 Recent phase II and phase III RCTs using combination therapy have demonstrated a survival advantage over monotherapy. 6 However, the value of combination immunotherapy remains controversial. Despite the demonstrated survival benefit, several studies have questioned whether better survival rates justify the increased toxicity. 14, 15 The added benefit of each drug may not be commensurate with the added risk of toxicity.
14 Second, the degree of added benefit varies between the added drugs. Furthermore, main mechanisms of combination immunotherapy have been discussed in two related reviews, 16, 17 however, their clinical translation are still unclear. A dialogue between preclinical researches and clinical findings is required for the next generation of tumor treatments.
To date, few meta-analyses have looked at combination immunotherapy. In this study, we conducted a meta-analysis of the efficacy and safety of combination immunotherapy and of monotherapy, taking into accounts the added benefits and toxicity of each drug.
Method and Material

Study design and search strategy
This meta-analysis was based on data from published clinical trials that compared combination of ICI therapies with monotherapy. We searched for trials on PubMed/Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar; April 2017 was the cut-off date. Key words included combination immunotherapy, immune checkpoint inhibitor plus dacarbazine, immune checkpoint inhibitor plus vaccine, PD-1 plus CTLA-4, nivolumab plus ipilimumab, nivolumab plus vaccine, and nivolumab plus dacarbazine. We included only studies published in English. Reference lists of related articles and articles recommended by Google Scholar or PubMed were checked to search for additional publications, and all additional studies of potential interest were retrieved for further analysis. 
Data extraction
Three reviewers (YW, KJ, MQ) independently extracted data with a piloted extraction form, and checked all data carefully. We identified all studies by first author and the year of publication, and extracted the following information from the reports: Year of publication, inclusion or exclusion criteria, sample size, drugs and doses in the experimental groups and control groups, PFS, OS, ORR and grade 3/4 treatmentrelated adverse events. The initial outcomes measured in the meta-analysis were the ORR and OS. Secondary outcomes included the PFS and the rate of grade 3/4 immune-related adverse events. All the duplicated studies were excluded.
Risk of bias assessment
Three reviewers (YW, KJ, MQ) independently assessed the risk of bias using the Cochrane Collaboration tool. All disagreement was resolved by the first author (YW). Details on the risk of bias in eight studies are illustrated in Supporting Information Figure S4 .
Statistical analysis
Statistical analysis, forest plots, and detection of publication bias were done with Stata SE 14 (StataCorp, College Station, TX). Risk of bias was calculated using Review Manager (RevMan5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). ln(HR) values and se(ln(HR)) values were calculated using an Excel spreadsheet developed by Matthew Sydes and Jayne Tierney of the MRC Clinical Trials Unit, London, UK. 18, 19 Odds ratios (ORs) and hazard ratios (HRs) were used for evaluation and 95% confidence intervals (CIs) were calculated for each estimate. p 0.05 was considered statistically significant. Heterogeneity was considered low, moderate or high for I 2 values <25%, 25-50% and >50%, respectively. 20 All analyses (ORR, OS, PFS, and grade 3/4 treatment-related adverse events) were performed using a random-effects model (I-V heterogeneity). Publication bias was assessed by both Begg's test and Egger's test.
What's new?
Immune checkpoint inhibitors (ICIs) are robust antitumor agents that have been explored extensively in clinical trials as monotherapy for different cancer types. Recent studies have begun to also examine ICI use in combination immunotherapy, though whether the benefits outweigh potential toxicities remains uncertain. This meta-analysis suggests that in lung cancer and melanoma patients, overall survival, progression-free survival, and overall response rate can be improved by ICI combination immunotherapy. A potential combination identified was nivolumab-ipilimumab-sargramostim. Most ICI combinations, however, produced a higher rate of adverse events compared with ICI monotherapy.
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Results
Search results
The trial selection process is illustrated in Supporting Information Figure S1 . Eight studies were included. We updated the data of one study 21 with information from a later report. 22 All the studies assessed the efficacy of combination immunotherapy, combining ICIs with other ICIs or with other therapies. We found multiple types of combination trials: Three combinations of various ICIs (n 5 1,340), one combination of an ICI and dacarbazine (n 5 502), one combination of an ICI and sargramostim (n 5 245), two combinations of an ICI, paclitaxel, and carboplatin (n 5 334), and one combination of an ICI and a gp100 vaccine (n 5 676).
The main characteristics of the trials are shown in Table 1 .
The clinical translation of combined treatment on the foundation of ipilimumab is summarized in Figure 1 .
Population characteristics
In total, data from 3,097 patients were included in the efficacy analysis, of whom 2,547 had melanoma and 550 had lung cancer. The safety analysis included 2,390 of these patients. The patients had been diagnosed with advanced melanoma, metastatic melanoma, non-small cell lung cancer, or small-cell lung cancer. A total of 1,523 patients received combination therapies, including a combination of various ICIs (n 5 524), a combination of an ICI and dacarbazine (n 5 250), a combination of an ICI and sargramostim (n 5 123), two combinations of an ICI, paclitaxel, and carboplatin (n 5 223), and a combination of an ICI and a gp100 vaccine (n 5 403). Patients who received monotherapy (n 5 1,534) served as the controls.
Efficacy
The ORR was reported in all eight studies. 21, [23] [24] [25] [26] [27] [28] [29] The PFS was reported in six of the studies. 21, [23] [24] [25] [26] [27] The OS was reported in seven of the studies.
21,23,25-29
The ORR and OS of combination therapy were significantly higher than those of monotherapy (Fig. 2) . A combination of ICIs and other therapies was associated with significantly higher ORRs than monotherapy (relative risk [RR]: 1.51, 95% CI: 1.03-2.20, p 5 0.034) (Fig. 2a) . Overall, combination therapy resulted in a significantly prolonged OS compared with monotherapy (HR: 0.86, 95% CI: 0.78-0.95, p 5 0.000) (Fig. 2b) . The PFS of combination therapy was significantly higher than that of monotherapy (HR: 0.93, 95% CI: 0.72-1.14, p 5 0.000) (Fig.  2c) . There was high heterogeneity in the ORR (I , and Supporting Information Table S1 , respectively. Cancer type did not exert a statistically significant clinical effect on ORR, OS, or PFS. The main features of these combinations were summarized in Figure 1 .
Safety
The toxicity of combination ICI immunotherapy was reported in all eight studies. 21, [23] [24] [25] [26] [27] [28] [29] We found a significantly higher rate of grade 3/4 treatment-related adverse events that Table S2 , respectively. Cancer type did not exert a statistically significant clinical effect on grade 3/4 treatment-related adverse events. The main features of these combinations were summarized in Figure 1 .
Publication bias and sensitivity analysis
A sensitivity analysis was conducted by recalculating the RR of various subgroups of studies based on relevant features; detailed information is included in Supporting Information Figure S2 . No sensitivity analysis yielded positive results. Based on Begg's test and Egger's test for small-study effects, there was no publication bias. In Egger's test, the p values were 0.622 for ORR, 0.441 for grade 3/4 treatmentrelated adverse events, 0.347 for OS, and 0.387 for PFS; the Egger graphs are shown in Supporting Information Figure  S3 . In Begg's test, the continuity-corrected p values were 0.536 for ORR, 0.649 for grade 3/4 treatment-related adverse events, 0.462 for OS, and 0.174 for PFS.
Discussion
To the best of our knowledge, this is the first meta-analysis to assess the efficacy and safety of combination ICI therapy, providing insights into the optimal combinations of ICIs. Outcomes of trials on combination ICI therapy have only been published recently, and the clinical value of combination ICI therapy is still controversial. Hence, we performed subgroup analyses to identify factors that would generate better clinical outcomes and a better added benefit against the toxicity of each additional drug.
Main findings
The pooled analyses indicated that combination ICI immunotherapy was associated with significantly improved PFS, OS and ORR in comparison with ICI monotherapy alone. However, most combinations will induce higher toxicity. The relationship between combined-ICI and clinical features (ORR, OS, PFS, G3/4 trAEs) was visualized in Figure 1 . This meta-analysis manifested that preclinical discoveries and clinical results are not totally correlative.
Among all combination immunotherapies assessed, combining nivolumab with ipilimumab yielded the best ORR. Combining an ICI with sargramostim, paclitaxel plus carboplatin, and dacarbazine improved ORR. In contrast, ICI combined with a gp100 vaccine yielded a lower ORR than monotherapy.
Improvements in OS were documented in almost all combinations. Both nivolumab and ipilimumab combination therapy and an ICI and dacarbazine therapy improved PFS significantly, while a combination of ICI and sargramostim was associated with only slight PFS improvement. In terms of the toxicity of combination ICI immunotherapy, we found that a combination of ipilimumab and sargramostim was the best choice. Combining an ICI with paclitaxel and carboplatin or with another ICI induced a higher rate of grade 3/4 treatment-related adverse events. The highest rate was observed for the combination of an ICI and dacarbazine.
Our meta-analysis indicates that adding nivolumab is more beneficial in PFS and ORR, and the addition of sargramostim appears to reduce the toxicity of ICIs. The efficacy and safety of combining nivolumab, ipilimumab and sargramostim should be investigated further for its potential to extend the clinical success of immunotherapies.
Agreement/disagreement with previous meta-analyses
Previous meta-analyses have evaluated the efficacy of ICIs. [30] [31] [32] [33] [34] [35] [36] [37] [38] Some concluded that combination immunotherapy could result in better antitumor efficacy, but were based on only one or two studies. 31, 38 One network meta-analysis compared ICIs with targeted therapies for metastatic melanoma, suggesting that a combination of BRAF and MEK inhibitors was superior to anti-CTLA-4 agents and anti-PD-1 agents. As far as we know, no other meta-analysis assessed the added benefits against the toxicity of each drug in the combination.
Limitations
The studies we included evaluated the treatment agents in multiple types of cancer with different etiologies and disease courses. In addition, some of the studies only reported short follow-up periods, and long-term outcomes were lacking. Moreover, a phase I/II trial (n 5 216) 23 was included where the treatment groups were not randomized. Lastly, the median PFS and median OS were not available in some of the reports. 24, 25, 27 Further study of updated information is required.
Conclusion
This meta-analysis found that the addition of nivolumab to ipilimumab showed more benefits in PFS and ORR among all the combinations. Sargramostim was associated with better OS and safety. The efficacy and safety of a nivolumabipilimumab-sargramostim combination should be investigated further.
